Hisamitsu Pharmaceutical Co Inc (JP:4530)

:4530

4530

Hisamitsu Pharmaceutical Co

RESEARCH TOOLSreports

Want to see JP:4530 full AI Analyst Report?

Hisamitsu Pharmaceutical Co (4530) Price & Analysis

2 Followers

4530 Stock Chart & Stats

¥4020.00

-¥16.00(-0.39%)

At close: Jan 08 4:00 PM EST

¥4020.00

-¥16.00(-0.39%)

Day’s Range― - ―

52-Week Range¥3,861.00 - ¥6,695.00

Previous CloseN/A

Volume86.40K

Average Volume (3M)139.59K

Market Cap

¥440.91B

Enterprise Value¥319.02B

Total Cash (Recent Filing)¥118.13B

Total Debt (Recent Filing)¥2.65B

Price to Earnings (P/E)22.5

Beta0.33

Next Earnings

Jul 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.43%

Share Statistics

EPS (TTM)102.79

Shares Outstanding75,164,894

10 Day Avg. Volume146,500

30 Day Avg. Volume139,593

Financial Highlights & Ratios

PEG Ratio-2.46

Price to Book (P/B)1.47

Price to Sales (P/S)2.64

P/FCF Ratio45.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)292.6

Revenue Forecast (FY)¥168.50B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetExtremely low debt-to-equity provides durable financial flexibility and downside protection. This conservative financing profile reduces refinancing and solvency risk, enabling steady R&D, selective capex or M&A and stability through industry cycles over the medium term.

Steady Revenue Growth & Durable MarginsMulti-year top-line growth (2026: ~5.3%) combined with consistently high gross margins (~56–60%) signals ongoing demand and structural pricing power in core products. Durable margins help absorb cost swings and support reinvestment in marketing and product R&D over coming quarters.

Core Transdermal Product FranchiseA focused franchise in transdermal and topical patch formulations is a structural competitive advantage. Proprietary formulation expertise, established brands and multi‑channel distribution create barriers to entry and support stable domestic and international revenue streams.

Bears Say

Uneven Free Cash Flow ConversionVolatile free cash flow despite positive operating cash flows makes funding allocation less predictable. Inconsistent FCF limits reliable dividends, buybacks or reinvestment in weaker years and increases execution risk for strategic investments over the medium term.

Profitability Dip In 2026A notable net margin decline in 2026 reflects operating profitability volatility, suggesting margin compression or cost pressures. If sustained, lower margins will reduce free cash flow and constrain reinvestment or returns, requiring structural fixes to restore prior profitability.

Moderate ROE / Capital EfficiencyROE in the mid-to-high single digits, paired with extremely low leverage, implies modest capital efficiency. Conservative financing reduces risk but also caps shareholder returns; without higher operating returns or better capital deployment, long‑term shareholder value growth may remain limited.

Hisamitsu Pharmaceutical Co News

Hisamitsu Wins Approval for Share Consolidation Ahead of Exchange Delisting

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an announcement. Hisamitsu Pharmaceutical has secured shareholder approval for a...

5d ago

Hisamitsu Pharmaceutical Proposes New Board Slate With Limited Changes

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an update. Hisamitsu Pharmaceutical has announced a slate of 10...

9d ago

Hisamitsu Profit Slips as Revenue Rises Ahead of Taiyo Kosan-Led Delisting

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has shared an update. Hisamitsu Pharmaceutical reported fiscal 2026 net sales of...

9d ago

Hisamitsu to Cancel All Treasury Shares Ahead of Planned Share Consolidation

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical will cancel 4,763,348 of...

1M ago

Hisamitsu Pharma Sets Shareholder Vote on Share Consolidation Ahead of Planned Delisting

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an update. Hisamitsu Pharmaceutical’s board has resolved to convene an...

1M ago

Taiyo Kosan Wins Control of Hisamitsu Pharmaceutical After Successful Tender Offer

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an announcement. Taiyo Kosan Co., Inc. has successfully completed its...

2M ago

Hisamitsu Sets Record Date for Potential MBO-Linked Shareholder Meeting

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical will set February 28,...

2M ago

TAIYO KOSAN Amends Tender Offer Filing for Hisamitsu Pharmaceutical After U.S. Antitrust Waiting Period

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has shared an announcement. Hisamitsu Pharmaceutical and its affiliate TAIYO KOSAN Co.,...

3M ago

Hisamitsu President’s Vehicle TAIYO KOSAN Launches Tender Offer to Boost Stake

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). TAIYO KOSAN CO., INC. has launched...

3M ago

Hisamitsu Board Backs CEO-Led MBO and Recommends Shareholders Tender Stock

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical’s board of directors has...

3M ago

4530 FAQ

What was Hisamitsu Pharmaceutical Co Inc’s price range in the past 12 months?

Hisamitsu Pharmaceutical Co Inc lowest stock price was ¥3861.00 and its highest was ¥6695.00 in the past 12 months.

What is Hisamitsu Pharmaceutical Co Inc’s market cap?

Hisamitsu Pharmaceutical Co Inc’s market cap is ¥440.91B.

When is Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date?

Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date is Jul 09, 2026 which is in 78 days.

How were Hisamitsu Pharmaceutical Co Inc’s earnings last quarter?

Hisamitsu Pharmaceutical Co Inc released its earnings results on Apr 13, 2026. The company reported ¥102.79 earnings per share for the quarter, beating the consensus estimate of N/A by ¥102.79.

Is Hisamitsu Pharmaceutical Co Inc overvalued?

According to Wall Street analysts Hisamitsu Pharmaceutical Co Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hisamitsu Pharmaceutical Co Inc pay dividends?

Hisamitsu Pharmaceutical Co Inc pays a Notavailable dividend of ¥60 which represents an annual dividend yield of 2.43%. See more information on Hisamitsu Pharmaceutical Co Inc dividends here

What is Hisamitsu Pharmaceutical Co Inc’s EPS estimate?

Hisamitsu Pharmaceutical Co Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hisamitsu Pharmaceutical Co Inc have?

Hisamitsu Pharmaceutical Co Inc has 75,164,894 shares outstanding.

What happened to Hisamitsu Pharmaceutical Co Inc’s price movement after its last earnings report?

Hisamitsu Pharmaceutical Co Inc reported an EPS of ¥102.79 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Hisamitsu Pharmaceutical Co Inc?

Currently, no hedge funds are holding shares in JP:4530

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hisamitsu Pharmaceutical Co Inc

Hisamitsu Pharmaceutical Co., Inc. is a Japan-based company primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products, with a strong focus on transdermal drug delivery systems. The company operates in various sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and medical devices. Core products include analgesics, anti-inflammatory medications, and treatments for various medical conditions, leveraging their expertise in patch technology and innovative drug formulations.